Prognostic Factors in Surgically Managed Gastrointestinal Stromal Tumours

Author： Wu X-J   Zhang R-X   Chen G   Fang Y-J   Ding P-R   Li L-R   Lu Z-H   Kong L-H   Pan Z-Z   Wan D-S  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.40, Iss.5, 2012-09, pp. : 1904-1911

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacotherapy of gastrointestinal stromal tumours

By Eisenberg Burton L   von Mehren Margaret  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 869-874

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate: In the Treatment of Gastrointestinal Stromal Tumours

By Croom K.F.   Perry C.M.  

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

By Nilsson Bengt   Nilsson Ola   Ahlman Håkan  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 457-468

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

By Huse Daniel M.  

Clinical Drug Investigation, Vol. 27, Iss. 2, 2007-01 ,pp. : 85-93

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

By Theou-Anton Nathalie   Faivre Sandrine   Dreyer Chantal   Raymond Eric  

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 717-734

Adis International

Access to resources Recommend Favorite